In NSC290956-treated mice, the ERK and AKT phosphoproteins in tumor sections were markedly decreased, which confirmed that the in vivo efficacy of NSC290956 is correlated with the impairment of KRas-mediated signaling. The gene discussed is KRAS; the disease is neoplasm.